COMMUNIQUÉS West-GlobeNewswire

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
06/11/2025
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/11/2025
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Seer Reports Third Quarter 2025 Financial Results
06/11/2025
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended [...]
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
06/11/2025
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant [...]
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
06/11/2025
– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from [...]
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
06/11/2025
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at the Stifel 2025 [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
06/11/2025
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
06/11/2025
Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the [...]
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of [...]
Nephros Announces Strong Third Quarter Financial Results; Achieving Highest Level of Programmatic Sales in Company History
06/11/2025
Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability SOUTH ORANGE, NJ., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: [...]
Omada Health Reports Third Quarter 2025 Results
06/11/2025
Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE [...]
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
06/11/2025
New capability to provide tailored and coordinated care informed by behavioral insights SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider [...]
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI ® net revenue was $ [...]
SRx Health Solutions Provides Response Related to Unusual Market Trading Activity Received by the NYSE American Exchange
06/11/2025
TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its [...]
Mesa Labs Announces Second Quarter Results
06/11/2025
LAKEWOOD, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Globus Medical Reports Third Quarter 2025 Results
06/11/2025
AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide [...]
AMN Healthcare Announces Third Quarter 2025 Results
06/11/2025
Quarterly revenue of $634 million and adjusted EBITDA of $58 million ; GAAP income of $0.76 /share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the [...]
Certara Reports Third Quarter 2025 Financial Results
06/11/2025
Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025
06/11/2025
GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]

Pages